Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative, potential pathogenic gram-positive bacteria

A technology of Gram-negative bacteria and Gram-positive bacteria, applied in the oral cavity to regulate bacterial colonization, the field of immunity, to reduce the risk of inflammation and infection, and improve the effect of protective immune process

Inactive Publication Date: 2004-09-01
SOC DES PROD NESTLE SA
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] While LPS from Gram-negative bacteria is known for its pro-inflammatory effects on immune cells, little work has been done with LTA from Gram-positive organisms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative, potential pathogenic gram-positive bacteria
  • Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative, potential pathogenic gram-positive bacteria
  • Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative, potential pathogenic gram-positive bacteria

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1: Lipoteichoic acid from Lactobacillus johnsonii NCC 533 strain and Lactobacillus acidophilus NCC 90 strain antagonizes the response of human intestinal epithelial cells to LPS or Gram-negative bacteria

[0068] Materials and methods

[0069] Cells, Media and Reagents

[0070] The human colon adenocarcinoma cell line HT29 was obtained from the American Type Culture Collection (ATCC, Manassas, VA. ATCC: HTB-38). at 5% CO 2 Undifferentiated cells were maintained in glucose-containing DMEM supplemented with 10% fetal calf serum (FCS; AmimedBioConcept, Allschwill, Switzerland) at 37°C in an incubator / air incubator, while differentiated cells were maintained in glucose-free grow in medium. Change the medium every two days until the cell monolayer reaches 90% confluency. Human peripheral blood mononuclear cells (PBMC) were isolated from heparinized adult blood donors by density gradient centrifugation with Ficoll-Isopaque (Pharmacia). The isolated PBMCs were was...

Embodiment 2

[0096] Example 2: Baby food

[0097] To obtain infant formula, we prepare a mixture containing in 100 ml: 0.5-5%, preferably 2% peptide; 0.2-10%, preferably 4% fat; 1-25%, preferably 8% % non-fructan carbohydrates (including 65% lactose, 20% maltodextrin, 15% starch); at least 10 6 cfu / ml of the following strains: Lactobacillus acidophilus NCC90 (CNCM I-2332) or Lactobacillus johnsonii NCC 533 (CNCM I-1225); trace amounts of vitamins and minor elements required daily; 0.01-2%, preferably 0.3% minerals; and 50-90%, preferably 75% water.

Embodiment 3

[0098] Example 3: Use in dairy products

[0099] According to the present invention, one or several strains of Lactobacillus acidophilus NCC 90 (CNCM I-2332) or Lactobacillus johnsonii NCC 533 (CNCM I-1225) can be used to prepare fermented yogurt-like milk products.

[0100] For this purpose, 1 liter of milk product containing 2.8% fat supplemented with 2% skim milk powder and 6% sucrose was prepared. It was pasteurized at 96°C for 30 minutes and then cooled to 42°C. Precultures of non-thickening strains of Streptococcus thermophilus and non-sticky strains of Lactobacillus bulgaricus in sterile MSK medium containing 10% reconstituted milk powder and 0.1% commercial yeast extract Reactivate.

[0101] Precultures of one or several strains were also reactivated in media containing 10% reconstituted milk powder and 0.1% commercial yeast extract with 1% sucrose. Pasteurized milk products were inoculated with 1% of each reactivated preculture and fermented at 32 °C until pH 4.5 w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a composition for modulating the immune responses induced by Gram negative bacteria, potential pathogenic Gram positive bacteria and / or their derivatives, comprising lipoteichoic acid from lactic acid bacteria as an active ingredient. It also relates to the use of a lipoteichoic acid from lactic acid bacteria as an active ingredient and / or lactic acid bacteria producing it and / or its supernatant of culture, in the manufacture of a medicament, an oral or topical product for cosmetic, dermatological or ophthalmological applications, a food or petfood composition for modulating bacterial colonisation, immune responses and decreasing the inflammatory processes associated with bacterially-mediated disease and infection in the gastrointestinal tract, bone, skin, eye, ear, lung and oral cavity. The invention also relates to lipoteichoic acid selected thereof.

Description

technical field [0001] The present invention relates to a composition for modulating an immune response induced by Gram-negative bacteria, possibly pathogenic Gram-positive bacteria and / or their derivatives, said composition comprising a lipophosphotea from lactic acid bacteria acid as the active ingredient. The invention also relates to lipoteichoic acid from lactic acid bacteria and / or the lactic acid bacteria producing it and / or the culture supernatant thereof as active ingredient in the preparation of pharmaceutical, oral or topical products for cosmetic, dermatological or ophthalmic applications , use in food or pet food for modulating bacterial colonization, immune response, reducing inflammatory processes associated with bacterial mediated diseases and infections in the gastrointestinal tract, bone, skin, eye, ear, lung and oral cavity. The present invention also relates to specific lipoteichoic acids. Background technique [0002] At parturition, the previously ste...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A23L1/30A61K8/00A61K8/72A61K8/96A61K8/99A61K31/7032A61K31/739A61K35/74A61P1/04A61P11/00A61P17/00A61P19/02A61P27/02A61P27/16A61P29/00A61P31/04A61P37/02A61Q11/00A61Q19/00C12P19/44
CPCA61K31/739A23V2002/00A61Q19/00A23L1/3014C12P19/44A61Q11/00A61K8/72A61K8/99A23L33/135A61P1/04A61P11/00A61P17/00A61P19/02A61P27/02A61P27/16A61P29/00A61P31/04A61P37/02A23V2250/206A61K35/74A61K9/0095A61K31/70
Inventor K·维达尔A·东内一胡赫斯D·-A·格拉纳托I·科尔特斯-托伊拉兹
Owner SOC DES PROD NESTLE SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products